Pfizer posted a new Phase 3 trial (VESPER-6) of once-monthly berobenatide (PF-08653944) in overweight/obesity, the day's only first-in-registry pivotal-class registration from a priority sponsor. — 2 trials with material updates.

Competitive Intelligence · Obesity and Type 2 Diabetes

Wednesday, May 20, 2026

Pfizer posted a new Phase 3 trial (VESPER-6) of once-monthly berobenatide (PF-08653944) in overweight/obesity, the day's only first-in-registry pivotal-class registration from a priority sponsor.

Key Signals · 2 trials updated

  • Pfizer registered VESPER-6 (NCT07595549), a Phase 3 randomized, double-blind, placebo-controlled trial of once-monthly subcutaneous berobenatide (PF-08653944) in overweight/obesity — 4 active dose arms vs placebo, n=954, primary endpoint % body-weight change at Week 72; est. start 2026-06-02, PCD 2028-05-04.
  • Differentiator: once-MONTHLY dosing vs the once-weekly standard for tirzepatide/semaglutide — a convenience/adherence play; trial carries an EU CTIS registration (2026-525318-75-00) alongside US, signaling US+EU pivotal footprint.
  • Novo Nordisk registered a new Phase 1 study (NCT07597018) comparing blood levels of "different versions" of cagrilintide in overweight/obesity (n=234, NOT_YET_RECRUITING) — a PK comparability/bridging study pointing to reformulation or next-gen manufacturing work on the amylin analog.
  • No other material deltas: ~15 standing Lilly/Novo trials (retatrutide-CLBP NCT07035093, SURMOUNT-ADOLESCENTS-2 NCT06439277, REDEFINE 3 CagriSema-CV NCT05669755, AMAZE 2/12 NNC0487-0111, NNC0662-0419) showed LastUpdatePostDate bumps only — no status, PCD, or enrollment change — classified administrative noise.

Material signals (last 24h, window 2026-05-19 → 2026-05-20)

1. Pfizer — Phase 3 berobenatide (PF-08653944), VESPER-6 — NEW REGISTRATION

NCT07595549 · StudyFirstPostDate 2026-05-19 (genuine first registry posting) · NOT_YET_RECRUITING

  • Design: Phase 3, randomized, double-blind, placebo-controlled, parallel-group. 4 experimental dose arms of PF-08653944 vs matching placebo.
  • Route/schedule: subcutaneous, once monthly — the key competitive differentiator against once-weekly tirzepatide and semaglutide.
  • Population: adults BMI ≥30, or ≥27 with ≥1 weight-related comorbidity (incl. T2D); n=954 (est.).
  • Endpoints: primary = % change from baseline in body weight at Week 72; secondaries include ≥5/10/15/20/25% responder rates, HbA1c, lipids, blood pressure, and Food Noise Questionnaire.
  • Timeline: est. start 2026-06-02; PCD 2028-05-04; SCD 2028-06-21. ~20-month participant duration.
  • Geography: EU CTIS registration (2026-525318-75-00) present → US + EU4-grade footprint, consistent with pivotal geographic intent.
  • Read: "VESPER-6" implies an established Phase 3 program (VESPER-1–5 predecessors); Pfizer is committing a tracked molecule to a large, long-duration pivotal-class obesity study with a differentiated monthly dosing profile.

2. Novo Nordisk — Phase 1 cagrilintide PK comparability — NEW REGISTRATION

NCT07597018 · StudyFirstPostDate 2026-05-19 · NOT_YET_RECRUITING · Phase 1 · n=234

  • Compares blood levels (PK) after multiple doses of different versions of cagrilintide in adults with overweight/obesity.
  • Material as a new priority-sponsor (any-phase) registration involving a tracked molecule. The "different versions" framing signals formulation/comparability or next-gen manufacturing work on the amylin analog (relevant to the CagriSema franchise and any standalone cagrilintide program).

Classified NOISE (LastUpdatePostDate bump only, no material delta)

All first-posted months/years ago; no status transition, PCD/SCD amendment, enrollment change, or results posting identified in the window:

  • NCT07035093 Lilly retatrutide in obesity + chronic low back pain (P3)
  • NCT06937099 Lilly mirikizumab + tirzepatide in Crohn's + obesity (P3) — note: tirzepatide co-admin, but mirikizumab (IL-23) is not a tracked MOA, so not a tracked-MOA combination
  • NCT06439277 Lilly tirzepatide SURMOUNT-ADOLESCENTS-2 (P3)
  • NCT06672549 Lilly pediatric obesity platform LY900040 (P3)
  • NCT05669755 Novo REDEFINE 3 CagriSema CV-outcomes (P3, ACTIVE_NOT_RECRUITING)
  • NCT07503210 Novo AMAZE 12 / NNC0487-0111 (P3); NCT07533175 Novo AMAZE 2 / NNC0487-0111 (P3); NCT07415954 Novo NNC0662-0419 (P2) — all tracked molecules, but updates administrative
  • NCT06289504 Novo CagriSema DDI (P1, COMPLETED 2024-11) and NCT04469855 Novo Ozempic PMS (COMPLETED 2025-05) — completions are stale, not new transitions

Out-of-scope hits returned by the molecule/condition pass and excluded: Pfizer ponsegromab cachexia (NCT06989437); Cascade CS060380 MASH (NCT07466017); Univ. Minnesota and Victor Chang academic studies.

Scope hygiene (proposed additions — not yet applied to query)

1. Kailera Therapeutics / KAI-9531 — NCT07284901 is a Phase 3 (n=1,700, RECRUITING) once-weekly GLP-1/GIP candidate in obesity + diabetes. Strong direct competitor to tirzepatide/MariTide but neither the sponsor nor molecule is on the watchlist. Recommend adding Kailera to tracked_sponsors and KAI-9531 to tracked_molecules.

2. Novo Nordisk NNC1679-0001 — NCT07570992, a Phase 1 in healthy/T2D (first post 2026-05-06), is a Novo asset not on the molecule list. Caught only via the priority-sponsor any-phase pass. Recommend adding NNC1679-0001 to tracked_molecules to make it auditable independent of the sponsor sweep.

These are flagged for review rather than silently added, per the Scope hygiene rule, to preserve the watchlist audit trail.

Generated by Claude Code + ClinicalTrials.gov MCP · clinicaltrials.gov
Rendered: 2026-05-20T12:12:39.826Z · prompt f8ca428e6d80